Ironwood Pharmaceuticals, Inc. (IRWD)
-NasdaqGS 14.39 
0.21(1.44%) May 17, 4:00PM EDT|After Hours
:
14.62 0.23 (1.58%) May 17, 5:32PM EDT
| Prev Close: | 14.60 |
|---|
| Open: | 14.41 |
|---|
| Bid: | 10.42 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 16.73 |
|---|
| Beta: | 1.68 |
|---|
| Next Earnings Date: | 17-Jul-13 |
|---|
| Day's Range: | 14.25 - 14.70 |
|---|
| 52wk Range: | 10.01 - 19.67 |
|---|
| Volume: | 1,255,069 |
|---|
| Avg Vol (3m): | 926,962 |
|---|
| Market Cap: | 1.56B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013Business Wire(Tue, May 14)
- Top Life Science Investors Of 2013at Forbes(Thu, May 9)
- Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care ConferenceBusiness Wire(Tue, May 7)
- Analyst downgrades Ironwood Pharma on expensesAP(Mon, May 6)
- Ironwood Pharmaceuticals Enters Oversold Territory (IRWD)at TheStreet(Wed, May 1)
- The Compelling Science Behind Synergyat Seeking Alpha(Mon, Apr 29)
- The Best- And Worst-Performing Biotech Stocks, April 19 to April 26at Forbes(Sat, Apr 27)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, Apr 27)
- IRONWOOD PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, Apr 26)
- David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc., Interviews with The Wall Street Transcript: Opportunities in Hepatitis C and Genomic TechnologiesWall Street Transcript(Fri, Apr 26)
- 3 Stocks Underperforming Today In The Health Services Industryat TheStreet(Thu, Apr 25)
- Synergy On Sale: Why This Opportunity Shouldn't Be Missedat Seeking Alpha(Thu, Apr 25)
- Loss Widens at IronwoodZacks(Wed, Apr 24)
- Nicor Gets a Thumbs Down and 4 More Analyst Downgrades To Knowat Wall St. Cheat Sheet(Wed, Apr 24)
- Ironwood downgraded to Underperform from Neutral at Wedbushtheflyonthewall.com(Wed, Apr 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 11.17 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.74 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.68 |
|---|
| Mean Recommendation*: | 2.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The companys lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable...
View More